First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer.
- Author:
Zhong-zhen GUAN
1
;
Dong-geng LIU
;
Bao-ming YU
;
Wei-qin WU
;
De SHI
;
Yu ZHAO
;
Yu-quan WEI
;
Li-qun ZOU
;
Xiao-ding WU
;
Wen ZHUANG
;
Feng-yi FENG
;
Pin ZHANG
;
Shi-ying YU
;
Hui-hua XIONG
;
Qiang FU
;
Shu ZHENG
;
Jian-jin HUANG
;
Gang WU
;
Chuan-yong YANG
;
Sheng-rong SUN
;
Qing-lan RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antimetabolites, Antineoplastic; therapeutic use; Capecitabine; Colorectal Neoplasms; drug therapy; mortality; Deoxycytidine; adverse effects; analogs & derivatives; therapeutic use; Female; Fluorouracil; analogs & derivatives; Humans; Male; Middle Aged; Survival Rate
- From: Chinese Journal of Oncology 2004;26(2):119-121
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer.
METHODSFrom December 2000 to November 2001, sixty patients with advanced and recurrent colorectal cancer received first-line capecitabine treatment given at a dose of 1250 mg/m(2) twice daily, on days 1 - 14 every 21 days. At least 2 cycles were administered.
RESULTSThe overall response rate was 23.3% with 14 PR, 24 SD (40.0%) and 15 PD. The median survival time was 14.7 months. The survival rate was 63.9% at 12-months and 33.4% at 24-months. Grade III-IV adverse effects were diarrhea in 4 patients (6.6%), anemia in 2 (3.3%) and hand-foot syndrome (HFS) in 1 (1.7%); Grade I-II adverse effects were hyperpigmentation in 20 (33.3%), HFS in 18 (30.0%) and diarrhea in 10 (16.7%).
CONCLUSIONCapecitabine is an efficacious and better-tolerated alternative treatment for the patients with advanced and recurrent colorectal cancer.
